Immuno-Colombia: Overview of immunotherapy




Fig. 3. Treatment with anti-CTLA-4 reduces the growth of established runn. Groups of mice were injected subcutaneously with 2 × 10° 51BLim10 tumor cells. Control animals (n = 10) were injected intraperitoriesly with 100 μg of imelevant hamster antibody on days 0, 3, 6, and 9, as indicated by the upward-pointing amoves. One arti-CTLA-4 treatment group (n = 10) received intraperitoriesl injections on the same days. The other treated mice in = 5 were over intraperitorial injections.



IUIS-ALACI-ACAAI
Immuno-Colombia 2021
course took place
remotely between 5th
to 16th April. The

theme of this meeting was "Mechanisms and Approaches to
Immunotherapy for Cancer and Chronic Inflammatory Diseases".
This article highlights a talk by Professor Carla Rothlin: An introductory overview of immunotherapy.




Fig. 3. Treatment with anti–CTLA-4 reduces the growth of established tumor. Groups of mice were injected subcutaneously with 2×10^6 51BLim10 tumor cells. Control animals (n = 10) were injected intraperitoneally with 100 μg of irrelevant hamster antibody on days 0, 3, 6, and 9, as indicated by the upward-pointing arrows. One anti–CTLA-4 treatment group (n = 10) received intraperitoneal injections on the same days. The other treated mice (n = 5) were given intraperitoneal injections of anti–CTLA-4 beginning on day 7 and subsequently on days 10, 13, and 16 (downward-pointing arrows).

Professor Rothlin began by giving a brief history of cancer

immunotherapy, starting with the first documented description of the tumour immune infiltrate by Virchow in 1863. She then highlighted the discovery of Coley's toxin, a combination of heat-killed streptococcal bacterium and Serratia marcescens, in 1898 by William Coley used to treat malignant tumours. However, immunotherapeutic use of use Coley's toxin was discontinued due to limitations such as no standardised protocol for the production and administration of Coley's toxin, and induction of heterogeneous immune responses that did not always lead to anti-tumour immunity. These keys factors and the identification of immune cells over the last century has enabled the development of many cancer immunotherapies that target specific immune cell functions.




She presented data that showed that administration of anti-CTLA-4 in mice after injection of 51 Blim 10 tumour cells induced a reduction of tumour size and was associated with robust tumour control. This study illustrated that T cells are a potential target for anti-tumour therapy. Additionally, research led by Gordon Freeman and Tasuku Honjo showed the critical role of inhibition of PD-1 by its ligands PDL1 and PDL2 results in the negative regulation of T cells responses in cancer immunotherapy. However, the main inconvenience with using these T cell response inhibitors is the high heterogenicity in their ability to control tumour growth.

She also highlighted two limitations of the cancer immunotherapy involving T cells checkpoints blockade:


- In cancer that has been relatively responsive to T cell checkpoint blockade (Melanoma, renal, lung and bladder cancer), treatment is only effective in a subset of patients
- Some types of cancer, such as pancreatic, prostate or brain tumours, are unresponsive to treatment.

Other immunotherapies currently being tested target dendritic cells and macrophages using immune checkpoint inhibitors such as TYRO3, AXL and MERTK. Prof Rothlin presented data from her research group that showed that



tumour infiltrating macrophages in YUMM 1.7 (Yale University Melanoma model) and MC38 (colorectal cancer) models express MERTK. She then demonstrated that MERTK ablation significantly improved the survival of MC38 mice by limiting tumour growth but not YUMM 1.7 mice. Differences in response rates between the two cancer models were attributed to (i) the low level of inflammatory macrophages and (ii) lower proportions Batf3+ dendritic cells in the YUMM proliferating monocyte and 1.7 murine model compare with MC38 mice. Thus, demonstrating that anti-tumour immunotherapy based on MERTK inhibition is not effective against all cancer types. This further highlights one of the major limitations of current anti-tumour immunotherapies. She also provided evidence that demonstrated that CD8+ T cells are required for a successful anti-tumour response, while CD4+ T cells are dispensable.

Sitravatinib significantly improves survival in the MC38 tumor model



Finally, Prof. Rothlin presented research on the use of Sitravatinib (from MIRATI therapeutics), a pharmacological inhibitor of MERTK, alone or in combination with α -PD1 in the MC38 tumour murine model. She showed that Sitravatinib alone or in combination with α -PD1 significantly improves survival in the MC38 tumour model.

- Interested in a detailed introduction to cancer immunotherapy? Read advanced pre-course material on Overview of Immunotherapy.
- <u>Full lecture recording available at IUIS-ALACI-ACAAI</u> Immuno-Colombia 2021 Lecture week 1.

References

- Chen D, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 2013, 39: 1-10.
- Kaufman H, et al. The promise of Immuno-oncology: implications for defining the value of cancer treatment. Journal for Immunotherapy of Cancer 2019, 7:129.
- Esfahani K, et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020, 27 (S2): 87-97.
- Rothlin C, et al. TAM Receptor Signaling in Immune Homeostasis. *Annu Rev Immunol*. 2015, 33: 355–391.

Article by Ulrich Femoe Membe